Research programme: oral biotherapeutics - Rani Therapeutics

Drug Profile

Research programme: oral biotherapeutics - Rani Therapeutics

Alternative Names: Adalimumab oral - Rani Therapeutics; Etanercept oral - Rani Therapeutics; Insulin oral - Rani Therapeutics

Latest Information Update: 26 Oct 2016

Price : $50

At a glance

  • Originator Rani Therapeutics
  • Class Anti-TNF monoclonal antibodies; Insulins; Peptides; Proteins; Recombinant fusion proteins; Vaccines
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Diabetes mellitus; Inflammation

Most Recent Events

  • 11 Oct 2016 Rani Therapeutics has 30 patents issued and more than 80 patents filed
  • 06 Jan 2016 Rani Therapeutics and MedImmune agree to conduct feasibility studies for oral delivery of injectable drugs for Metabolic disorders
  • 04 Sep 2013 Research programme: oral biotherapeutics - Rani Therapeutics is available for partnering as of 04 Sep 2013. http://www.ranitherapeutics.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top